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Clinical Nutrition 
 
Girona (Catalonia, Spain), January 28th, 2019 
 
Dear Editor, 
 
As you certainly may know, since the discovery of membrane-derived extracellular vesicles 
(EVs) as vehicles for exchange of regulatory microRNAs (miRNAs), RNA-based cell-to-cell 
communication through plasma EVs has attracted many studies endorsing the idea that EVs 
and their cargo are of most relevance in physiology and physiopathology. The major challenge 
is the understanding of how (or whether) RNA-containing circulating EVs induce changes in 
metabolism and stimulate the response of target cells. So far, the characterization of RNA-
based cell-to-cell communication through plasma EVs under physiological conditions is still 
scarce and needs to be further assessed.  
 
While we previously reported on determinants for obesity and type 2 diabetes of microRNAs 
found in plasma and adipose tissue 1-8, the study entitled “Comparative and functional analysis of 
plasma membrane-derived extracellular vesicles from obese vs. nonobese women” aimed to investigate 
their presence in isolated plasma EVs. Thereby, the relation of parameters affecting these 
biomarkers in obese women and age-matched healthy-weight controls was investigated. Then, 
functional analyses in human adipocytes were conducted to try to shed additional light on 
functional differences in lean-obese plasma EVs. This critical step in validation of EVs as 
functional contributors to metabolic changes accomplished in vitro relied on the identification 
of correlations between clinical outputs and specific EVs-contained miRNA signatures found in 
obese patients, which, in the future, may be determined in rapid and convenient fashion using 
EVs-driven biosensors and therapeutical signals leading to cardiometabolic protection against 
obese-related disturbances.  
 
We believe that this information may be helpful to design strategies to determine and improve 
the metabolic profile of obese patients, and that this manuscript has high interest for scientific 
and medical community, and hence for the readers of Clinical Nutrition. 
 
Yours sincerely, 
 
Francisco J. Ortega, Ph.D. 
Section of Diabetes, Endocrinology and Nutrition (UDEN) 
Girona Biomedical Research Institute (IDIBGI) 
Hospital Universitario de Girona Dr. Josep Trueta 
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ABSTRACT 50 
 51 
Background: Membrane-derived extracellular vesicles (EVs) are released to the circulation by 52 
cells found in adipose tissue, transferring microRNAs (miRNAs) that may mediate the adaptive 53 
response of recipient cells. This study investigated plasma EVs from obese vs. nonobese women 54 
and their functional impact in adipocytes.  55 
 56 
Methods: Plasma EVs were isolated by differential centrifugation. Concentration and size were 57 
examined by nanoparticle tracking analysis (NanoSight). RNA was purified from plasma and 58 
plasma EVs of 45 women (47 ± 12 years, 58% of obesity) and profiles of mature miRNAs were 59 
assessed. Functional analyses were performed in human adipocytes. 60 
 61 
Findings: Smaller plasma EVs were found in obese when compared to nonobese women. 62 
Positive associations were identified between circulating EVs numbers and parameters of 63 
impaired glucose tolerance. Almost 40% of plasma cell-free miRNAs were also found in 64 
isolated plasma EVs, defined as Ct values<37 in ≥75% of samples. BMI together with 65 
parameters of insulin resistance were major contributors to EVs-contained miRNA patterns. 66 
Treatments of cultured human adipocytes with EVs from obese women led to a significant 67 
reduction of genes involved in lipid biosynthesis, while increasing the expression of IRS1 68 
(12.3%, p=0.002). 69 
 70 
Interpretation: Size, concentration and the miRNA cargo of plasma EVs are associated with 71 
obesity and parameters of insulin resistance. Plasma EVs may mediate intercellular 72 
communication relevant to metabolism in adipocytes. 73 
 74 
Funding: SAF2015-66312 (FIS, to JMF-R), CIBEROBN (ISCIII), PERIS 2016, 440/C/2016 75 
(MTV3, to FJO), FI-DGR 2015 (AGAUR, to JL), FEDER. 76 
77 
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INTRODUCTION 78 
 79 
Cells can release to the circulation membrane-embedded extracellular vesicles (EVs) that, based 80 
on their composition, nature and size, are grouped into different classes. The majority of EVs 81 
occur within the sub-micron range (30–1,000 nm), where small vesicles of different origin 82 
appear to be the most abundant EVs subclass, present in the lowest size range (≤200 nm) [1]. 83 
EVs from human plasma are a mixture of microparticles, exosomes, and other vesicular 84 
structures. The potential of plasma EVs for diagnosis and prognosis of different diseases is 85 
being intensely investigated, as changes in circulating EVs may give important information 86 
related to silent disease and early metabolic impairment [2]. Notably, elevated concentration of 87 
plasma EVs have been identified in a number of pathological disorders, including 88 
cardiovascular disease [3]. The association between adiposity, EVs-markers, and metabolic 89 
syndrome has been tested in patients with clinically manifest vascular disease, in association 90 
with subcutaneous and visceral fatness [4]. On the other hand, in vitro and in vivo treatments 91 
with plasma microparticles from patients with metabolic syndrome provided evidence that 92 
circulating EVs may influence endothelial dysfunction to some extent [5].  93 
To the best of our knowledge, none of the previous studies have investigated the 94 
relationship between circulating EVs’ properties and clinical parameters in subjects without 95 
manifest cardiovascular or metabolic disease. The aim of this work was to characterize 96 
circulating EVs obtained from a group of healthy lean and obese women and determine the 97 
biophysical properties and the miRNA content of these EVs. Then, we provide some functional 98 
analysis in human adipocytes to ascertain their activity in regulating gene expression in 99 
recipient cells as previously [6], as a proxy of their functionality. We also provide a comparison 100 
of the miRNA EVs content to that of the whole plasma miRNA profiles in these individuals. 101 
Our results suggest that circulating EVs have distinct biophysical and contain biological 102 
molecules capable of regulating gene expression relevant to metabolism in human adipocytes.  103 
104 
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RESEARCH DESIGN AND METHODS 105 
 106 
Subject recruitment 107 
Forty-five women aged between 30 and 70 year-old (47 ± 12 years), including 58% of obesity 108 
(body mass index (BMI) ≥ 30 kg/m2), were enrolled at the Endocrinology Service of the 109 
Hospital Universitari Dr. Josep Trueta de Girona (Girona, Spain) for plasma membrane-derived 110 
extracellular vesicles (EVs) isolation and microRNA (miRNA) profiling in both plasma and 111 
isolated plasma EVs. Inclusion criteria were i) absence of acute or systemic disease, and ii) 112 
absence of infection within the previous month. None of the subjects recruited were under 113 
medication or had evidence of metabolic disease. Liver disease and thyroid dysfunction were 114 
specifically excluded by biochemical work-up.  115 
 116 
Clinical measurements 117 
BMI was calculated as weight (in kilograms) divided by height (in meters) squared. Percent fat 118 
mass was measured using the Tanita BIA scale (Tanita Corporation, Tokyo, Japan). The 119 
subjects’ waist was measured with a soft tape midway between the lowest rib and the iliac crest. 120 
The hip circumference was measured at the widest part of the gluteal region. The waist-to-hip 121 
(WtH) ratio was then calculated. Blood pressure was measured in the supine position on the 122 
right arm after a 10-min rest. A standard sphygmomanometer of appropriate cuff size was used 123 
and the first and fifth phases were recorded. Values used in the analysis are the average of three 124 
readings taken at 5 min intervals. Blood samples were withdrawn after an overnight fast 125 
between 8:00 and 9:00 a.m. Serum glucose was measured in duplicate by the glucose oxidase 126 
method with a Beckman Glucose Analyzer 2 (Brea, CA). The coefficient of variation (CV) was 127 
1.9%. Serum insulin was measured in duplicate using a monoclonal immunoradiometric assay 128 
(Medgenix Diagnostics, Fleunes, Belgium). The inter and intra-assay CVs were 6.9 and 4.5% at 129 
14 and 89 µIU/l, respectively. Insulin resistance was calculated in all subjects using the HOMA-130 
IR value [glucose (mmol/l) × insulin (µIU/l) / 22.5], as previously described [7]. Lipid profile 131 
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(triglycerides, total cholesterol, and high and low-density lipoproteins) were measured by 132 
enzymatic methods on a Hitachi 917 instrument (Roche, Mannheim, Germany). Whole blood 133 
hemoglobin levels (EDTA sample, Coulter Electronics, Hialeah, FL) were determined by 134 
routine laboratory tests. Glycated hemoglobin (HbA1c) was measured by the high-performance 135 
liquid chromatography method (Bio-Rad, Muenchen, Germany). Intra and inter-assay CVs were 136 
less than 4% for all these tests. High-sensitive C reactive protein (CRP) was measured by a 137 
turbidimetric assay on the Integra 800 analyser (Roche). Participants were requested to withhold 138 
alcohol and caffeine for at least 12 h prior to the different tests, and were non-smokers.  139 
 140 
Isolation and characterization of plasma EVs 141 
Plasma was obtained by standard venepuncture and centrifugation using EDTA-coated 142 
Vacutainer tubes (Becton-Dickinson, Franklin Lakes, NJ). The separation was performed by 143 
double-centrifugation using a laboratory centrifuge (Beckman J-6M Induction Drive Centrifuge, 144 
Beckman Instruments Inc., Palo Alto, CA). The first spin was performed at 1,000 × g for 15 min 145 
at 4ºC. The second spin was performed at 2,000 × g for 5 min at 4ºC. Plasma samples from each 146 
participant were processed to isolate circulating EVs, as previously described [8]. Briefly, 5 ml 147 
of plasma EDTA were diluted with 15 ml of cold sterile phosphate buffered saline (PBS) and 148 
centrifuged twice, at 2,000 × g and 12,000 × g for 45 min, to remove any remaining cellular 149 
debris. Then, supernatants were collected and ultracentrifuged at 100,000 × g 4ºC for 140 min. 150 
Next, supernatants were discarded and pellets were resuspended in 10 ml of cold PBS, before a 151 
filtering step using sterile 10 ml syringes and 0.22 μm adjustable filters. Additional 152 
ultracentrifugation of 75 min was carried out at 100,000 × g and 4°C. Finally, pellets of plasma 153 
EVs were resuspended with 100 µl of cold and sterile PBS, aliquoted and stored at -80ºC until 154 
subsequent analysis and characterization, RNA extraction and functional tests.  155 
For transmission electron microscopy (TEM), isolated small plasma EVs suspensions 156 
were fixed in 4% paraformaldehyde for 60 min. EVs suspensions from 6 different samples 157 
(approximately 10 μl) were applied to copper mesh Formvar coated carbon stabilized grids, 158 
were allowed to adsorb to the grid for 20 min and then were wicked off with filter paper. For 159 
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negative staining, 1% Aqueous Uranyl Acetate (10 μl) was applied to the grid for 2 min, then 160 
wicked off with Whatman filter paper. Grids were allowed to thoroughly dry before viewing 161 
(Figure 1A) with a JEOL JEM 1010 transmission electron microscope (JEOL USA Inc., 162 
Peabody, MA), operated at 80 kV and equipped with a SC1000 ORIUS® CCD Camera (Gatan 163 
Inc., Pleasanton, CA). Nanoparticle tracking analysis (NTA) is a powerful technique that 164 
combines the properties of laser light scattering microscopy and Brownian motion, in order to 165 
obtain size and distribution of microparticles in liquid suspension [9]. Plasma EVs size 166 
distribution and concentrations were determined by means of a Malvern Nanosight NS300 167 
Instrument (Malvern Instruments Ltd, UK), as explained by Vestad et al. [10]. Dilutions of 168 
1:200 in PBS were injected into the NanoSight chamber. The camera gain was set at a constant 169 
value of 10, and the threshold value for microvesicle detection was set at 5. The NTA intra-170 
assay (i.e. within-day, n=16) variation was as follows (mean ± SE, min.-max.): particle 171 
concentration (particles/ml): 713,625,000 ± 41,024,583 (259,000,000-1,310,000,000); particles 172 
per frame: 36 ± 2 (13-67); centers per frame: 39 ± 3 (15-66); particle mean diameter: 118.92 ± 173 
4.6 (101.5-137). Inter-assay (day-to-day, n=5) coefficients of variation for plasma EVs 174 
preparations ranged from 5% to 20%. Results were retrospectively studied in association with 175 
anthropometrical and biochemical variables, and were used for normalizing the amount of EVs 176 
suspension and plasma sample used in each experiment. 177 
 178 
MicroRNA profiling in plasma and isolated plasma EVs 179 
Total RNA content was extracted from ~2 million plasma EVs and an equivalent amount of 180 
paired-plasma samples by methods aimed at preserving and isolate small RNA molecules 181 
(mirVana PARIS Isolation Kit, Applied Biosystems, Darmstadt, Germany). A fixed volume of 3 182 
µl RNA solution from the 40 µl-eluate was used as input into the reverse transcription (RT), 183 
using the TaqMan miRNA Reverse Transcription Kit and the TaqMan miRNA Multiplex RT 184 
Assays, which are required to run the TaqMan® Array human MicroRNA A+B Cards Set v2.0 185 
(Life Technology, Darmstadt, Germany). Pre-amplification was performed using TaqMan 186 
PreAmp Master Mix and Megaplex™ PreAmp Primers for either human Pool Set A and B, 187 
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which provide an optional pre-amplification step prior to real-time analysis when sensitivity is 188 
of the utmost importance and/or the sample is limiting. Profiling of 754 mature miRNA species 189 
was carried out by means of Taqman low density array cards, as previously explained [11, 12]. 190 
The screening was performed in 6 pools of samples, comprised of either isolated EVs or paired-191 
plasma samples, so 12 miRNA arrays were carried out. Plasma and isolated plasma EVs from 192 
each participant were merged together before sample processing and miRNA profiling. The 193 
identification subgroup was comprised of 18 carefully preselected participants. The 194 
characteristics of the subjects that were eligible for pooling and miRNA profiling are shown in 195 
Supplemental Table 1. Samples were pooled together in groups of three. These pools were 196 
intended to be representative for each study group (3 obese vs. 3 nonobese groups). Three pools 197 
were aimed at identifying miRNAs contained in obese EVs (BMI ≥ 30 kg/m2), while the other 198 
three were comprised of samples from lean participants (BMI < 25 kg/m2). Semi quantitative 199 
real time-PCR was carried out on an Applied BioSystems 7900HT thermocycler. Data was 200 
analyzed with SDS Relative Quantification Software version 2.2.2, with an assigned minimum 201 
threshold above the baseline of all assays showing measurable amplification above background. 202 
In this discovery samples, “mean” normalized values (“DeltaCt”) were obtained as the raw Ct 203 
value – average of raw Cts for all miRNAs with reliable results (Ct values ≤ 37) in each pool 204 
(Supplemental Figure 1). The “relative quantification” measures the presence of specific 205 
miRNAs and is calculated in each sample as 2ˆ(-“DeltaCt”) for each sample. Fold-changes reflect 206 
differences for values of this “relative expression” between groups of subjects.  207 
Commercially available TaqMan hydrolysis probes (Applied Biosystems, Darmstadt, 208 
Germany; Supplemental Table 2) were used to assess the presence of individual miRNA 209 
candidates in all samples (n=45). The pre-amplification product was diluted 1:200 previous 210 
being combined (5 μL) with 0.25 μL of TaqMan miRNA hydrolysis probes (20x), and 4.75 μL 211 
of the LightCycler 480 Probes master mix (2x) (Roche Diagnostics, Barcelona, Spain) to a final 212 
volume of 10 μL. Gene expression was assessed by real-time PCR using the LightCycler® 480 213 
Real-Time PCR System (Roche Diagnostics, Barcelona, Spain). For the analysis by qRT-PCR, 214 
we evaluated first a suitable number of reference (or “housekeeping”) miRNAs, based on their 215 
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expression stability, and according to the GeNorm methodology implemented in the R package 216 
SL qpcrNorm (Bioconductor) [13]. Then, we used “DeltaCt” normalization procedures based on 217 
the most stable (or “rank invariant”) miRNAs in plasma EVs, as implemented in the HTqPCR R 218 
package [14]. Thus, the geometric mean of these selected internal controls (i.e. miR-30c, miR-219 
24, and miR-484) was used as reference, as previously reported [15]. All analyses were carried 220 
out in parallel within the same day. We excluded Ct values higher than 37 in the semi-221 
quantitative assessment, and higher than 34 when evaluating the qualitative enrichment of EVs-222 
contained miRNAs. Three qRT-PCR replicates and positive and negative controls were 223 
included in all reactions. Intra-assay coefficients of variation were less than 12% for the most 224 
prevalent miRNAs in plasma EVs (i.e. miR-320, miR-186-3p, miR-323-3p, miR-106a, let-7b, 225 
miR-186, miR-146a, miR-106b). 226 
 227 
Impact of plasma EVs on human adipocytes: changes in gene expression 228 
Two thousand human subcutaneous preadipocytes from a non-diabetic Caucasian male with 229 
BMI < 30 kg/m
2
 and age < 40 y (Zen-Bio Inc., Research Triangle Park, NC) were cultured with 230 
Preadipocytes Medium (PM, Zen-Bio Inc.) in a humidified 37ºC incubator with 5% CO2. 231 
Twenty-four hours after plating cells in 12-well culture plates, preadipocytes were checked for 232 
confluence and differentiated using the commercially available Differentiation Medium (DM, 233 
Zen-Bio Inc.), following manufacturer’s instructions. Non-differentiated preadipocytes used as 234 
control for adipogenesis were maintained in PM. Two weeks after initializing differentiation, 235 
differentiated cells appeared rounded with large lipid droplets apparent in the cytoplasm. Cells 236 
were then considered mature adipocytes and incubated with fresh adipocytes medium 237 
containing ~250,000 plasma EVs/µl. These EVs were obtained from 6 obese and 6 lean women 238 
to assess functional differences regarding the impact in vitro of plasma obese-lean EVs. In 239 
parallel, THP-1 macrophages were treated for 24 h with 10 ng/ml lipopolysaccharide (LPS) 240 
obtained from Escherichia coli O111:B4 (Sigma Chemical Co.). The LPS-stimulated 241 
macrophage conditioned media (MCM) was collected and centrifuged at 400 × g for 5 min, 242 
diluted with adipocyte medium (2%) and used to induce in differentiated human adipocytes the 243 
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chronic low-grade inflammation state of obesity, as we have previously reported [12]. After 24 244 
h of treatment, cells were removed and stored at -80ºC for future analysis. 245 
Total RNA was purified from cells using miRNeasy® Mini Kit (QIAgen, Gaithersburg, 246 
MD). Cells were homogenized in 0.6 mL of QIAzol® Lysis Reagent (QIAgen), a monophasic 247 
solution of phenol and guanidine thiocyanate which facilitates sample disaggregation and 248 
inhibits RNAses. After addition of chloroform (0.4 volumes), the homogenate was separated 249 
into aqueous and organic phases by centrifugation (15 min at 12,000 × g and 4ºC). Then, the 250 
upper aqueous phase was isolated and ethanol absolute (1.5 volumes) was added, to provide 251 
appropriate binding conditions for RNA molecules. The sample was applied to a silica-252 
membrane RNeasy spin columns, where RNA binds to the membrane while phenols and other 253 
compounds are washed away. High quality RNA was finally eluted in 30 μL of RNAse-free 254 
water. Final RNA concentrations were assessed with a Nanodrop ND-1000 Spectrophotometer 255 
(Thermo Fischer Scientific, Wilmington, DE). The integrity was checked with the Nano lab-on-256 
a-chip assay for total eukaryotic RNA using Bioanalyzer 2100 (Agilent Technologies, Palo 257 
Alto, CA). The RNA integrity number (RIN) obtained was above 8 for all replicates. 258 
Three μg of total RNA were reverse transcribed to cDNA using High Capacity cDNA® 259 
Archive Kit (Applied Biosystems, Darmstadt, Germany) according to the manufacturers’ 260 
protocol. Expression was assessed by real time PCR using the LightCycler® 480 Real-Time 261 
PCR System (Roche Diagnostics, Barcelona, Spain), and TaqMan® technology suitable for 262 
relative gene expression quantification. The reaction was performed following manufacturers’ 263 
instructions in a final volume of 7 μL. The cycle program consisted of an initial denaturing of 264 
10 min at 95ºC then 45 cycles of 15 sec denaturizing phase at 92ºC and 1 min annealing and 265 
extension phase at 60ºC. Then, the crossing points (Cp) values were assessed for each 266 
amplification curve by the Second Derivative Maximum Method. The “DeltaCp” value was 267 
calculated by subtracting the Cp value for the corresponding endogenous controls in each 268 
sample from the Cp value for each target gene. Fold changes compared with the endogenous 269 
control were then determined by calculating 2ˆ(-“DeltaCp”), so gene expression results are expressed 270 
as expression ratio relative to preselected and validated housekeeping. The peptidyl-prolyl cis-271 
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trans isomerase A (PPIA), also known as cyclophilin A, was assessed as the most suitable 272 
endogenous control for gene expression in adipocytes [16]. The commercially available 273 
TaqMan® primer/probe sets used for measures of gene expression are listed in the 274 
Supplemental Table 2. Replicates and positive and negative controls were included in each 275 
reaction. 276 
 277 
Statistical analyses 278 
Descriptive results of continuous variables are expressed as mean ± standard deviation (SD). 279 
Before statistical analysis, normal distribution and homogeneity of the variances were evaluated 280 
using Levene’s test. ANOVA and paired t-tests were performed to study differences on 281 
quantitative variables between groups. The semi-quantitative concentrations for the different 282 
miRNAs were correlated with clinical parameters (Spearman’s test). Multiple linear regression 283 
models in a stepwise manner were constructed to evaluate the independent contribution of 284 
specific variables. Data analyses were performed with the SPSS
 
statistical software (SPSS 285 
V12.0 Inc., Chicago, IL), and the R Statistical Software (http://www.r-project.org/). miRNA 286 
targeting sequences within the miRNA sequence were checked using miRBase 287 
(http://www.mirbase.org/). Predicted target transcripts of miRNA candidates were collected and 288 
combined from databases such as TargetScanHuman (http://www.targetscan.org/), miRNA.org, 289 
and miRWalk (www.ma.uniheidelberg.de). In addition, blastn (http://www.clustal.org/) was 290 
used to detect additional similarities which were 7 base pairs or longer, and we explored the 291 
web-based repository TissueAtlas (https://ccb-web.cs.uni-saarland.de/tissueatlas) in order to 292 
assess the tissue origin of miRNAs contained in EVs. 293 
294 
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RESULTS 295 
 296 
Plasma EVs size and concentration are associated with obesity and parameters of 297 
impaired glucose tolerance 298 
The clinical characteristics of the 45 healthy women are shown in Table 1. Significant 299 
variations in particle size distribution (Figure 1B) depicted fairly smaller plasma extracellular 300 
vesicles (EVs) in women with grade I obesity (body mass index (BMI) of 30-35 kg/m
2
) (116.7 ± 301 
9.1 nm), and in women with BMI ≥ 35 kg/m2 (114.3 ± 8.6 nm), when compared to lean (122.6 ± 302 
5 nm) and overweight (124.6 ± 8.2 nm) participants (Figure 1C). Significant inverse 303 
associations (Spearman’s) were found between EVs diameter, BMI (r=-0.53, p=0.0002; Figure 304 
1D), and waist circumference (r=-0.43, p=0.014). The size of plasma EVs also correlated with 305 
fasting triglycerides, fasting insulin, and HOMA-IR, while being positively associated with 306 
HDL cholesterol (Table 2). BMI (p=0.014) and fasting triglycerides (p=0.045) contributed to 307 
explain 33.8% (p=0.001) of plasma EVs size, after controlling for age and fasting insulin in 308 
multiple linear regression models. On the other hand, independent and positive associations 309 
were identified between circulating concentrations of EVs and parameters of impaired glucose 310 
tolerance, such as fasting glucose (r=0.51, p=0.0006; Figure 1E) and glycated hemoglobin 311 
(r=0.32, p=0.042; Table 1). Interestingly, fasting glucose alone (p=0.002) accounted for 21.1% 312 
(p=0.007) of the variance in plasma EVs concentration, after adjusting for age and BMI. 313 
Altogether, current results point at significant differences affecting plasma EVs and being 314 
intrinsically and independently linked to increased fatness (size) and parameters of impaired 315 
glucose tolerance (concentration) in apparently healthy women. 316 
 317 
Plasma EVs-contained miRNA patterns are associated with obesity and HOMA-IR 318 
Plasma EVs-contained miRNA profiling was performed in plasma samples of 18 subjects that 319 
were merged together in 6 groups (3 obese vs. 3 nonobese groups) as detailed in the  methods 320 
section. The characteristics of these participants are detailed in Supplemental Table 1. In this 321 
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identification sample, one hundred miRNAs (± 16) showed Ct values <37 in isolated EVs. 322 
Under same conditions of RNA extraction, analysis and clustering, whole plasma showed 264 323 
(± 44) mature miRNA species, including the miRNAs found in isolated plasma EVs. No 324 
significant differences were identified between groups of subjects for the absolute amounts of 325 
RNA, or the number of miRNAs that can be quantified under such conditions (Supplemental 326 
Figure 2A). However, heatmap and clustering of miRNAs detection in EVs (but not in plasma) 327 
pointed out the existence of three groups of samples, instead of two (Supplemental Figure 2B). 328 
Conversely, BMI and parameters of insulin resistance such as fasting insulin and HOMA-IR 329 
seemed to be major contributors to miRNA patterns in plasma EVs (Figure 2). 330 
One important question was whether miRNA profiles assessed in EVs may indicate 331 
some sort of “selectivity” for miRNAs enriched within circulating EVs, with regard to the 332 
overall plasma miRNA population, as previously postulated [17]. To address this key question, 333 
we strengthened the conditions under which we considered indisputable the presence of 334 
miRNAs in both plasma and isolated plasma EVs, or only in plasma, now defined as Ct values < 335 
35 in all samples. Thereby, the recovery of 18% of plasma cell-free miRNAs was also prevalent 336 
in isolated plasma EVs of at least one group (Supplemental Figure 3). With these curated lists 337 
of miRNAs, we investigated whether there was a specific sequence in the subset of miRNAs 338 
that would be enriched in plasma EVs, which may act like a “zipcode” to target them into EVs 339 
[17]. However, the multiple sequence alignment analysis comparing the miRNAs found in 340 
plasma EVs revealed not common sequences explaining such enrichment (Supplemental 341 
Figure 3). On the other hand, we used these lists to dig into the tissue origin of plasma EVs-342 
contained miRNAs. As previously described in [18], the majority of these miRNAs fell in 343 
amiddle tissue specificity index (TSI) ranges, and was not specific for single tissues. 344 
Nonetheless, among EVs-contained miRNAs we observed miRNAs and miRNA families that 345 
were predominantly expressed in certain tissues, such as veins, thyroid gland, lung, skin, and 346 
also in adipocytes (e.g. MIR-17 family, Supplemental Figure 4), indicating these tissues as 347 
potential contributors to the miRNA repertoire of human plasma EVs. Obviously, such 348 
conclusions need to be further endorsed in additional follow-up studies. 349 
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Finally, miRNA candidates were analyzed in each sample, including the subjects 350 
selected for pooling and miRNA profiling. These validation procedures with individual assays 351 
shortlisted a subset of 8 EVs miRNAs that significantly differed between groups (Table 1). In 352 
partial agreement, EVs-associated miRNA candidates were associated with BMI, while others 353 
showed significant and independent association with biomarkers of incipient impaired glucose 354 
tolerance (e.g. fasting glucose, glycated hemoglobin), insulin resistance (fasting insulin, 355 
HOMA-IR), inflammation (C reactive protein), and dyslipidemia (fasting triglycerides, 356 
cholesterol) (Table 3). 357 
 358 
Impact of plasma EVs on gene expression in adipocytes 359 
Obesity leads to adipose tissue dysfunction, with deranged expression of adipokines and genes 360 
involved in glucose and lipid metabolism, resulting in insulin resistance and inflammation. We 361 
previously found that EVs from obese subjects impair insulin stimulated glucose uptake in 362 
cultured adipose cells [6]. To gather further insights into the biological effects of these EV 363 
isolated from obese and lean women, we sought to determine the changes in gene expression in 364 
adipose cells that may occur by direct transfer of miRNAs and other molecules found in these 365 
EVs. Therefore, we tested the hypothesis that EVs present in plasma of obese individuals may 366 
alter the expression of cytokines, reducing the production of insulin sensitizing factors and 367 
increasing the synthesis of molecules that may modulate metabolism in lipid-containing 368 
differentiated adipocytes. Acute treatments of 24 h with plasma EVs of obese women lead to 369 
significant reduction in the expression of genes involved in adipogenesis (e.g. GLUT4, 370 
ADIPOR1, CEBPA) and fatty acid biosynthesis (ACLY, ACACA, FASN, ELOVL6), while 371 
increasing the expression of IRS1 (12.3%, p=0.002), when compared to EVs of lean participants 372 
(Figure 3). Additional associations pointed the interrelationship between the BMI of donors and 373 
changes in the expression of CEBPA, FASN, GLUT4, IRS1, and ACLY, while measures of 374 
increased insulin resistance accounted for increased GLUT4, IRS1, and FASN, and decreased 375 
IL6, SREBF1, and ELOVL6 gene expression in adipocytes (Supplemental Table 4). 376 
377 
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DISCUSSION 378 
 379 
Since the discovery of plasma membrane-derived extracellular vesicles (EVs) as “vehicles” for 380 
exchange of regulatory microRNAs (miRNAs), RNA-based cell-to-cell communication through 381 
EVs has attracted many studies endorsing the concept that circulating EVs and their cargo are of 382 
most relevance in physiology and physiopathology [19, 20]. Many of these EVs are released to 383 
the circulation by a variety of cells found in adipose tissue [21], including macrophages [22], 384 
mesenchymal stem cells [23, 24], and adipocytes [21, 25, 26]. These plasma EVs may elicit 385 
both autocrine and paracrine effects but information regarding their distribution size, 386 
concentration and miRNA content in obese subjects is scarcely available and could provide 387 
important information to understand the development of metabolic syndrome in this population.  388 
Trying to determine the extent to which obesity contributes to plasma EVs and EVs-389 
contained miRNAs, we isolated EVs from the plasma of 45 women who varied widely in terms 390 
of obesity and fat mass (14 to 66% of their body weight). Then, we dissected differences 391 
regarding plasma EVs size, concentration and the miRNA content among lean, overweight, and 392 
obese participants. These circulating vesicles were fairly smaller in obese women than in 393 
nonobese participants. Interestingly, the number of small EVs isolated from obese and lean 394 
participants was equivalent, but differed according to biomarkers of impaired glucose tolerance, 395 
such as fasting glucose and glycated hemoglobin. In agreement with this piece of data, 396 
genetically obese ob/ob mice displayed elevated numbers of circulating EVs when compared to 397 
lean wild-type controls [27], and an increased secretion of EVs was achievable in adipocytes 398 
following exposure to biological stimuli related to the chronic low-grade inflammation state of 399 
obesity, even though no variations in size were reported [28]. On the other hand, higher 400 
circulating levels of EVs have been found in obese patients [29], suggesting that enlarged fat 401 
depots may contribute to such increase. In agreement, EVs size distribution and concentrations 402 
indicated a nominal increase in the frequency of small EVs found in diabetic rats and humans 403 
[30]. Plasma EVs concentrations were also two-fold greater in gestational diabetic women, 404 
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when compared to matched pregnancies with normal glucose tolerance [31]. The current study 405 
identified significant variations in circulating EVs concentrations and size in close association 406 
with the BMI and parameters of glucose tolerance of apparently healthy women. From a clinical 407 
point of view, the results obtained here give promising evidence for future analyses using 408 
plasma EVs as an early and non-invasive diagnosis of obesity-associated metabolic 409 
disturbances. Obviously, additional studies are needed to confirm these associations. 410 
 411 
Relevance of miRNAs-containing plasma EVs in obesity 412 
Some of the abilities for fine-tuned regulation of metabolic properties have been ascribed to the 413 
miRNAs contained in adipose-derived plasma EVs [21]. Thus, monitoring expression signatures 414 
affected by plasma EVs from obese/lean subjects in cellular systems may shed some light on 415 
pathways that are regulated by circulating EVs targeting recipient cells. In this respect, different 416 
profiles of EVs containing miRNAs have been identified in mice feeding high-fat diet and 417 
leptin-deficient obese models, when compared to lean wild-type animals [25]. The study of 418 
Thomou et al. [21] pointed at the adipose tissue as a major source of circulating EVs-contained 419 
miRNAs, and demonstrated that adipocyte-derived circulating miRNAs are contained in plasma 420 
EVs that may display physiological functions in neighboring cells and farther tissues. These 421 
findings uncovered the potential role of adipose-derived miRNA-containing plasma EVs in the 422 
pathogenesis of metabolic diseases.  423 
PCR analyses with reverse transcription profiling of plasma EVs revealed the presence 424 
in plasma EVs of at least one-hundred miRNAs, accounting for around one third of the miRNAs 425 
that can be quantified in whole plasma. Here again, different profiles of miRNAs in plasma EVs 426 
were independently associated with BMI and parameters of insulin resistance. Previously, 427 
plasma exosome miRNA profiling unraveled 3 potential modulators of adiponectin in diabetes, 428 
affecting the glycemic index in poorly controlled diabetic patients [32]. In inflammatory 429 
microvesicles, miR-133, let-7, miR-17/92, miR-21, miR-29, miR-126, miR-146, and miR-155 430 
were found in association with metabolic and cardiovascular diseases [33]. An independent 431 
study revealed significant reduction of miR-126 in circulating EVs of patients with stable 432 
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coronary artery disease [34]. A group of miRNAs, including miR-21 and miR-126, was also up-433 
regulated in plasma EVs isolated from subjects with vulnerable coronary artery disease [35]. 434 
Our results, assessed in a well-characterized sample of apparently healthy women, identified at 435 
least 8 EVs-contained miRNA candidates related to BMI (e.g. let-7b, miR-146a), and showed 436 
discordant profiles linked to dislipidemia (miR-29c) and values of insulin resistance, including 437 
three miRNAs significantly associated with fasting insulin (i.e. miR-222/223, miR-26b). 438 
Thereby, the levels of circulating EVs-contained miRNAs might represent a fine-tuned 439 
biomarker of slightly variations in insulin sensitivity that may account in parallel to (or 440 
independently of) increased fat depots.  441 
 442 
Obese plasma EVs may compromise adipocyte commitment in vitro 443 
Even thought body tissues are exposed to plasma EVs of different origins, making difficult the 444 
analysis of specific contributions for each subset of EVs, plasma samples from obese patients 445 
are enriched in adipose-derived EVs, as previously indicated [27-29]. Conversely, adipocyte-446 
released EVs have shown autocrine functions [6, 36], regulating lipid deposition, proliferation, 447 
inflammation, the metabolism of neighboring cells, and modulation of the adaptive response in 448 
tissues and organs reached through the circulation [37].  449 
By treating cell cultures of adipocytes from the same donor with isolated plasma EVs 450 
from lean and obese women it was possible to characterize the contribution of circulating EVs 451 
to the inflammatory and metabolic state of adipocytes exposed to this plasma content. These 452 
experimental procedures were aimed at unravel the relevance of obese EVs in energy 453 
homeostasis and impaired metabolism. This critical step in validation of EVs as functional 454 
contributors to metabolic changes accomplished in vitro relied on the identification of 455 
correlations between clinical outputs and specific EVs-contained miRNAs found in obese 456 
patients. Thereby, 24 h of treatment with obese plasma EVs significantly reduced the expression 457 
of genes related to lipogenesis, without modifying neither inflammatory nor lipolytic aspects, 458 
when compared to lean EVs. Interestingly, only IRS1 showed increased expression in human 459 
adipocytes treated with plasma EVs from obese women, being more likely related to the fasting 460 
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insulin levels of these participants, which also correlated with changes in GLUT4 and FASN. In 461 
fact, plasma EVs showed different functional properties according not only to the fatness of the 462 
donors but also to biochemical aspects mirroring decreased insulin sensitivity. Moreover, the 463 
interpretation of miRNAs significantly up-regulated in obese EVs (e.g. hsa-miR-155-5p, hsa-464 
let-7b-5p, hsa-miR-146a/b-5p, hsa-miR-892b) identified target genes involved in fatty acid 465 
alpha oxidation and in both IGF1 and leptin signaling, through the potential modulation of 466 
experimentally validated target genes such as PTGS2 and STAT3. On the other hand, miR-301a-467 
3p and miR-145-5p were more likely found in plasma EVs from lean participants, and disclosed 468 
their specific involvement in leptin and the insulin receptor signaling through the ability of 469 
modulate PDE3B gene expression (Supplemental Table 5). To test this hypothesis, we 470 
evaluated whether genes harboring miRNA target sites for these miRNA candidates were 471 
differentially modulated in treated adipocytes. However, gene expression of these targets 472 
changed little if any in adipocytes under treatment with lean/obese EVs. In fact, changes 473 
affecting these genes in cell cultures were more likely related to metabolical outputs 474 
(Supplemental Table 4) than to the weight of donors or the presence/abundance of miRNA 475 
candidates. This points out the intricate nature of these “vehicles”, with dozens of regulatory 476 
miRNAs showing variations at both the qualitative (presence/absence) and quantitative (relative 477 
abundance) level, and suggests alternative mechanisms leading to the acute regulation of gene 478 
expression in adipocyte cultures under treatment with plasma EVs. Additional studies are 479 
needed before any more definite conclusion can be drawn. 480 
 481 
Conclusions 482 
Plasma EVs may contribute to energy homeostasis, being involved in metabolic disease 483 
development and progression, and may provide useful biomarkers for impaired metabolism. By 484 
deciphering the processes of physiological communication through EVs found in circulation, 485 
the understanding of mechanisms conducting to obesity-related morbidities may be unveiled. 486 
We report that in women with no clinically manifest of cardiovascular or metabolic disease, 487 
plasma EVs concentration, size and miRNA cargo were independently related to obesity and 488 
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parameters of insulin sensitivity. Concurrently, obese plasma EVs blunted the expression of 489 
genes involved in the synthesis of lipids in human adipocytes, compromising their activity in 490 
vitro. Altogether, current results identify miRNAs present in EVs during obesity in the absence 491 
of onset of disease, and suggest potential mechanisms underlying the role of plasma EVs in the 492 
development of adipose tissue dysfunction in obesity, paving the way for the development of 493 
new therapies and applications.  494 
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Table 1 Anthropometrical and biochemical characteristics of study women. 511 
 512 
 513 
All subjects BMI<30 kg/m
2
  30≤BMI<35 kg/m
2
 BMI≥35 kg/m
2
 ANOVA p-value
a
 
N (women) 19 12 14   
Age (years)  45.1 ± 15.1 49.9 ± 11.3 46 ± 8.8 0.574 0.848 
BMI (kg/m
2
)  24.8 ± 2.7 32.2 ± 1.5 38 ± 3.9 <0.0001 <0.0001 
Fat mass (%) 24.3 ± 4.2 42.1 ± 14.6 50.1 ± 13.1 <0.0001 <0.0001 
Waist (cm) 82.6 ± 9.0 94.7 ± 4.3 99.4 ± 5 <0.0001 <0.0001 
Hip (cm) 96.4 ± 6.1 106.5 ± 5.1 112.8 ± 2.9 <0.0001 <0.0001 
WtH ratio 0.87 ± 0.08 0.89 ± 0.03 0.88 ± 0.05 0.633 0.591 
SBP (mm Hg) 133.7 ± 25.7 125.3 ± 17.1 127.9 ± 8.9 0.510 0.442 
DBP (mm Hg) 77.2 ± 10.3 79.6 ± 7.3 78.1 ± 5.2 0.745 0.769 
Fasting glucose (mg/dl) 88.0 ± 9.3 92.2 ± 8.8 88.1 ± 13.4 0.562 0.984 
Insulin (µIU/ml) 5.25 ± 2.34 7.79 ± 3.02 7.86 ± 3.58 0.022 0.016 
HOMA-IR 0.97 ± 0.47 1.64 ± 0.75 1.74 ± 0.73 0.035 0.017 
Glycated haemoglobin (%) 4.59 ± 0.39 4.91 ± 0.3 4.95 ± 0.59 0.075 0.036 
Cholesterol (mg/dl) 200.7 ± 30.4 214.3 ± 50.9 208.9 ± 30 0.626 0.549 
HDL Cholesterol (mg/dl) 72.2 ± 14.3 60.8 ± 13.6 55 ± 9.9 0.002 0.001 
LDL Cholesterol (mg/dl) 112.3 ± 32.1 134 ± 43.4 134.9 ± 29.4 0.147 0.084 
Triglycerides (mg/dl) 80.6 ± 32.1 97.5 ± 54.8 95 ± 37.8 0.497 0.347 
   
   
Mean EVs diameter (nm) 123.5 ± 6.6 116.7 ± 9.1 114.3 ± 8.6 0.005 0.002 
EVs/ml plasma (x 10
6
) 4,394 ± 1391 3,964 ± 1824 4,378 ± 1549 0.725 0.977 
   
   
miR-320a-3p in EVs 0.1427 ± 0.1094 0.1485 ± 0.1064 0.3526 ± 0.2299 0.002 <0.001 
let-7b-5p in EVs 0.0271 ± 0.0278 0.0314 ± 0.0268 0.0934 ± 0.0863 0.004 0.001 
miR-186-3p in EVs 0.1 ± 0.071 0.0456 ± 0.0628 0.033 ± 0.0339 0.01 0.004 
miR-106a-5p in EVs 37.4 ± 29.46 75.51 ± 50.99 68.11 ± 38.51 0.02 0.022 
miR-323a-3p in EVs 0.6621 ± 0.6229 1.6962 ± 1.1418 1.1332 ± 0.96 0.024 0.117 
miR-146a-5p in EVs 0.2084 ± 0.1051 0.1709 ± 0.1171 0.1193 ± 0.0608 0.056 0.017 
miR-186-3p in EVs 0.0114 ± 0.0087 0.0049 ± 0.0039 0.0063 ± 0.0044 0.059 0.046 
miR-106b-5p in EVs 13.97 ± 14.62 21.64 ± 10.5 27.70 ± 25.4 0.116 0.042 
   
   
miR-320a-3p in Plasma 0.0907 ± 0.0902 0.1257 ± 0.0752 0.2363 ± 0.223 0.033 0.01 
let-7b-5p in Plasma 0.0469 ± 0.0275 0.0404 ± 0.0197 0.0488 ± 0.0229 0.797 0.844 
miR-186-3p in Plasma 0.1091 ± 0.0608 0.1047 ± 0.0803 0.0739 ± 0.0163 0.209 0.084 
miR-106a-5p in Plasma 1.12 ± 0.39 1.2 ± 0.64 0.97 ± 0.19 0.436 0.304 
miR-323a-3p in Plasma 0.0041 ± 0.0029 0.0062 ± 0.0034 0.0086 ± 0.0057 0.016 0.005 
miR-146a-5p in Plasma 1.84 ± 0.8 1.41 ± 1.25 2.56 ± 2.38 0.256 0.19 
miR-186-3p in Plasma 0.0412 ± 0.0335 0.0231 ± 0.0123 0.0286 ± 0.0211 0.266 0.222 
miR-106b-5p in Plasma 0.0813 ± 0.1012 0.0218 ± 0.016 0.0784 ± 0.1284 0.451 0.938 
 514 
Results are mean ± standard deviation. BMI: Body mass index, WtH: Waist to hip, 515 
SBP: Systolic blood pressure, DBP: Diastolic blood pressure, HOMA-IR: Homeostatic 516 
model assessment of insulin resistance, HDL: High-density lipoprotein, LDL: Low-517 
density lipoprotein, EVs: Extracellular vesicles. 
a
 Fisher’s least significant difference 518 
(LSD) post-hoc test was performed by comparing subjects with BMI≥35 kg/m2 vs. non-519 
obese participants (BMI<30 kg/m
2
) women. Significant differences (p<0.05) are shown 520 
in bold. 521 
522 
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Table 2 Correlations between the mean diameter of plasma EVs and circulating 523 
concentrations with clinical outputs in the whole cohort (n=45 women). 524 
 525 
 526 
BMI: Body mass index, WtH: Waist to hip, SBP: Systolic blood pressure, DBP: 527 
Diastolic blood pressure, HOMA-IR: Homeostatic model assessment of insulin 528 
resistance, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, EVs: 529 
Extracellular vesicles. Significant differences (Spearman’s p-value < 0.05) are shown in 530 
bold.  531 
 532 
533 
 Mean EVs diameter (nm) EVs/ml plasma 
Correlations r p r p 
Age (years)  -0.263 0.088 0.106 0.498 
BMI (kg/m
2
)  -0.525 <0.001 0.118 0.441 
Fat mass (%) -0.238 0.213 -0.179 0.353 
Waist (cm) -0.43 0.014 -0.31 0.085 
Hip (cm) -0.249 0.169 -0.18 0.323 
WtH ratio -0.308 0.081 -0.194 0.28 
SBP (mm Hg) -0.116 0.476 0.018 0.912 
DBP (mm Hg) -0.24 0.137 -0.155 0.341 
Fasting glucose (mg/dl) 0.014 0.93 0.506 <0.001 
Insulin (µIU/ml) -0.397 0.007 0.042 0.783 
HOMA-IR -0.333 0.031 0.289 0.063 
Glycated haemoglobin (%) -0.039 0.811 0.322 0.042 
Cholesterol (mg/dl) -0.114 0.473 -0.13 0.413 
HDL Cholesterol (mg/dl) 0.388 0.011 -0.225 0.152 
LDL Cholesterol (mg/dl) -0.172 0.275 -0.071 0.657 
Triglycerides (mg/dl) -0.444 0.003 0.125 0.43 
EVs/ml plasma 0.009 0.955   
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Table 3 Partial correlations between miRNAs assessed in plasma EVs and paired-534 
plasma samples and clinical outputs (n=45 women). 535 
 536 
Spearman’s Rho BMI (kg/m2) 
Fasting glucose 
(mg/dl) 
Fasting insulin 
(µIU/l) 
HOMA-IR CRP (mg/l) 
Triglycerides 
(mg/dl) 
Cholesterol 
(mg/dl) 
miR-320a-3p EVs 0.523 (0.001) 0.143 (0.386) 0.097 (0.584) 0.066 (0.716) 0.122 (0.546) 0.062 (0.715) 0.348 (0.035) 
miR-186-3p EVs -0.402 (0.011) 0.208 (0.204) -0.138 (0.437) -0.026 (0.884) -0.475 (0.011) 0.201 (0.233) 0.004 (0.982) 
miR-892b EVs 0.392 (0.012) -0.253 (0.115) 0.031 (0.858) 0.024 (0.893) 0.044 (0.822) 0.134 (0.422) 0.242 (0.144) 
miR-106a-5p EVs 0.381 (0.015) -0.21 (0.194) 0.029 (0.868) -0.055 (0.759) 0.203 (0.301) 0.057 (0.736) 0.254 (0.125) 
let-7b-5p EVs 0.363 (0.023) -0.07 (0.672) 0.060 (0.737) 0.044 (0.81) -0.026 (0.898) 0.06 (0.725) 0.096 (0.574) 
miR-186-5p EVs -0.342 (0.031) 0.150 (0.354) -0.135 (0.438) -0.127 (0.474) -0.490 (0.008) 0.164 (0.324) -0.115 (0.492) 
miR-146a-5p EVs -0.343 (0.032) 0.244 (0.135) 0.035 (0.843) 0.183 (0.309) -0.331 (0.086) 0.032 (0.849) -0.237 (0.159) 
miR-323a-3p EVs 0.317 (0.047) -0.138 (0.396) 0.024 (0.889) -0.059 (0.739) 0.126 (0.522) -0.092 (0.584) 0.198 (0.233) 
miR-26b-5p EVs 0.35 (0.05) 0.175 (0.338) 0.419 (0.029) 0.428 (0.026) 0.203 (0.353) 0.280 (0.127) 0.097 (0.603) 
miR-338-5p EVs 0.309 (0.053) -0.319 (0.045) 0.022 (0.898) -0.004 (0.983) -0.034 (0.863) 0.044 (0.791) 0.206 (0.215) 
miR-222-3p EVs 0.28 (0.089) 0.13 (0.437) 0.357 (0.041) 0.315 (0.079) -0.02 (0.924) -0.01 (0.954) 0.072 (0.675) 
miR-212-3p EVs 0.214 (0.184) -0.149 (0.36) -0.111 (0.525) -0.243 (0.166) 0.292 (0.132) 0.11 (0.513) 0.416 (0.009) 
miR-30a-5p EVs 0.193 (0.233) -0.337 (0.034) 0.001 (0.998) -0.043 (0.81) -0.153 (0.438) -0.029 (0.861) 0.136 (0.416) 
miR-342-3p EVs 0.183 (0.258) -0.15 (0.357) 0.069 (0.693) 0.047 (0.794) 0.116 (0.556) -0.339 (0.037) -0.111 (0.507) 
miR-150-5p EVs 0.151 (0.352) -0.089 (0.586) -0.113 (0.517) -0.072 (0.687) 0.407 (0.032) -0.101 (0.545) 0.116 (0.488) 
miR-374a-5p EVs -0.124 (0.46) -0.133 (0.428) -0.01 (0.956) -0.039 (0.83) 0.144 (0.481) -0.476 (0.003) -0.1 (0.564) 
miR-29c-3p EVs 0.06 (0.736) 0.019 (0.916) -0.083 (0.661) -0.183 (0.342) 0.232 (0.286) 0.309 (0.086) 0.535 (0.002) 
miR-27a-3p EVs -0.036 (0.826) -0.289 (0.07) -0.082 (0.642) -0.052 (0.769) -0.432 (0.022) -0.05 (0.765) -0.026 (0.876) 
miR-223-3p EVs -0.029 (0.86) 0.114 (0.485) 0.346 (0.041) 0.427 (0.012) -0.404 (0.033) 0.023 (0.893) -0.02 (0.906) 
        miR-320a-3p Plasma 0.245 (0.144) 0.076 (0.654) 0.123 (0.496) 0.133 (0.46) -0.168 (0.367) -0.069 (0.695) 0.201 (0.248) 
miR-186-3p Plasma -0.291 (0.069) 0.18 (0.266) -0.323 (0.055) -0.27 (0.111) -0.271 (0.133) 0.231 (0.163) 0.384 (0.017) 
miR-892b Plasma 0.194 (0.243) 0.24 (0.147) 0.1 (0.575) 0.106 (0.55) -0.103 (0.576) 0.321 (0.056) 0.218 (0.202) 
miR-106a-5p Plasma -0.103 (0.538) 0.148 (0.375) -0.076 (0.67) -0.064 (0.72) -0.27 (0.135) 0.245 (0.15) 0.342 (0.041) 
let-7b-5p Plasma -0.052 (0.76) -0.158 (0.351) -0.002 (0.99) -0.032 (0.86) -0.306 (0.101) -0.203 (0.241) -0.333 (0.051) 
miR-186-5p Plasma -0.293 (0.067) 0.041 (0.802) -0.196 (0.252) -0.197 (0.251) -0.393 (0.026) 0.029 (0.863) 0.08 (0.634) 
miR-146a-5p Plasma 0.082 (0.615) 0.116 (0.476) -0.144 (0.402) -0.109 (0.525) -0.239 (0.188) 0.166 (0.319) 0.4 (0.013) 
miR-323a-3p Plasma 0.209 (0.208) 0.082 (0.626) 0.011 (0.949) 0.021 (0.908) -0.074 (0.688) -0.049 (0.779) -0.016 (0.928) 
miR-26b-5p Plasma -0.185 (0.26) -0.051 (0.757) -0.268 (0.12) -0.241 (0.162) -0.083 (0.653) -0.183 (0.278) -0.102 (0.547) 
miR-338-5p Plasma 0.146 (0.382) 0.115 (0.491) 0.039 (0.828) 0.018 (0.92) -0.152 (0.406) 0.266 (0.117) 0.142 (0.409) 
miR-222-3p Plasma -0.136 (0.401) -0.144 (0.376) -0.152 (0.376) -0.123 (0.476) -0.059 (0.749) -0.089 (0.596) 0.012 (0.941) 
miR-212-3p Plasma -0.106 (0.525) -0.222 (0.18) -0.449 (0.008) -0.455 (0.007) -0.127 (0.487) 0.086 (0.62) 0.214 (0.209) 
miR-30a-5p Plasma -0.108 (0.512) -0.297 (0.066) -0.290 (0.091) -0.323 (0.059) -0.042 (0.819) -0.163 (0.336) 0.046 (0.786) 
miR-342-3p Plasma 0.206 (0.209) 0.197 (0.229) 0.155 (0.373) 0.271 (0.115) 0.224 (0.217) 0.143 (0.399) 0.106 (0.534) 
miR-150-5p Plasma 0.223 (0.172) 0.225 (0.169) 0.171 (0.327) 0.186 (0.284) 0.029 (0.873) 0.071 (0.678) -0.032 (0.85) 
miR-374a-5p Plasma -0.092 (0.576) 0.21 (0.2) 0.072 (0.679) 0.131 (0.453) 0.018 (0.92) 0.006 (0.973) -0.175 (0.3) 
miR-29c-3p Plasma -0.326 (0.049) -0.005 (0.979) -0.237 (0.184) -0.255 (0.152) -0.291 (0.113) -0.127 (0.467) 0.177 (0.308) 
miR-27a-3p Plasma -0.004 (0.982) 0.143 (0.38) 0.262 (0.122) 0.265 (0.118) -0.116 (0.526) 0.318 (0.052) 0.377 (0.019) 
miR-223-3p Plasma -0.009 (0.955) 0.13 (0.425) 0.17 (0.322) 0.177 (0.301) -0.081 (0.659) 0.016 (0.925) 0.135 (0.418) 
 537 
BMI: Body mass index, HOMA-IR: Homeostatic model assessment of insulin 538 
resistance, EVs: Extracellular vesicles. Significant differences (p<0.05) are shown in 539 
bold. 540 
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FIGURES LEGEND 660 
 661 
Figure 1 A. Microscopic analysis of the morphology of isolated plasma EVs using TEM and 662 
negative staining. B. NTA particle concentration according to the particle size in lean (BMI< 25 663 
kg/m
2), overweight (25≤ BMI< 30 kg/m2), and obese (30≤ BMI< 35 kg/m2; and BMI≥ 35 664 
kg/m
2
) women. C. Mean and 95% confidence interval for circulating EVs in each subgroup. D. 665 
Association between BMI and EVs size, and E. between fasting glucose and the concentrations 666 
of EVs found in plasma of lean (empty circles), overweight (diamonds), and obese participants 667 
with BMI of 30-35 kg/m
2
 (straight triangles), and ≥35 kg/m2 (inverted triangles). 668 
 669 
Figure 2 Indexes of correlation between miRNAs found in EVs and paired plasma samples and 670 
parameters of interest. BMI: Body mass index, HOMA-IR: Homeostatic model assessment of 671 
insulin resistance, HbA1C: Glycated haemoglobin, HDL: High-density lipoprotein, LDL: Low-672 
density lipoprotein, CRP: C reactive protein, EVs: Extracellular vesicles (size or numbers).  673 
 674 
Figure 3 Gene expression measures obtained in undifferentiated (PA) and differentiated mature 675 
adipocytes (MA) upon treatment with macrophage LPS-conditioned media (MCM) and plasma 676 
EVs isolated from 12 participants, grouped in “Lean” or “Obese” EVs according to the donors’ 677 
BMI. Three biological replicates were performed for each treatment. 678 
 679 
Figure 1 
A B 
C D E 
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Figure 2 
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Supplemental Table 1 Mean ± standard deviation for anthropometrical and 
biochemical parameters in women preselected for sample pooling, merge and miRNA 
profiling in plasma and isolated plasma EVs. Each column reports mean values of 3 
subjects, so the assessment included samples from 18 participants.  
 
Pools   Lean #1 Lean #2 Lean #3 Obese #1 Obese #2 Obese #3 Student t-test 
Age (years)  39 ± 16 40 ± 13 36 ± 6 44 ± 8 35 ± 2 45 ± 1 0.658 
BMI (kg/m2)  21.6 ± 2.7 22.4 ± 2.3 24.8 ± 0.4 36.9 ± 0.9 36.4 ± 2 40.7 ± 8.4 <0.0001 
Fat mass (%) 22.1 ± 2.7 19.2 ± 6.9 23.7 ± 1.2 55 ± 0.2 65.9 ± 0.7 34.2 ± 8.2 <0.0001 
Waist (cm) 81.3 ± 3.2 78.3 ± 5.3 85 ± 1.4 100.3 ± 1.8 98.0 ± 1.9 95.5 ± 9.2 <0.0001 
Hip (cm) 92.5 ± 4.9 90.3 ± 1.8 95.3 ± 3.2 115 ± 3.5 112.0 ± 4.5 111.3 ± 3.2 <0.0001 
WtH ratio 0.88 ± 0.01 0.87 ± 0.04 0.89 ± 0.04 0.87 ± 0.04 0.88 ± 0.12 0.86 ± 0.11 0.681 
SBP (mm Hg) 128.5 ± 17.7 148.5 ± 60.1 104 ± 4.2 126.5 ± 4.9 125.3 ± 4.5 125.5 ± 6.4 0.931 
DBP (mm Hg) 72 ± 4.2 80.5 ± 23.3 73 ± 1.4 80.5 ± 2.1 76.3 ± 5.5 76.7 ± 4.7 0.608 
Fasting glucose (mg/dl) 83.3 ± 4.2 80.7 ± 9 89 ± 7 96.3 ± 13.7 84.0 ± 4.4 99.3 ± 13.6 0.076 
Insulin (µIU/ml) 3.5 ± 1.3 6.8 ± 2.6 4.2 ± 2.1 7.8 ± 3.3 7.5 ± 1.7 7.4 ± 2.6 0.022 
HOMA-IR 0.7 ± 0.24 1.39 ± 0.61 0.90 ± 0.36 1.92 ± 1.01 1.56 ± 0.35 1.87 ± 0.83 0.013 
Glycated haemoglobin (%) 4.5 ± 0.7 4.8 ± 0.3 4.5 ± 0.5 5.4 ± 0.4 4.4 ± 0.3 5.3 ± 0.6 0.08 
Cholesterol (mg/dl) 175.3 ± 11 190.3 ± 38 218.7 ± 32.3 228.3 ± 26.7 182 ± 35 195.7 ± 14.2 0.633 
HDL Cholesterol (mg/dl) 66.7 ± 14.7 91.5 ± 18.7 67.7 ± 12.3 48.7 ± 11.3 54.6 ± 10.4 53.7 ± 12.4 0.004 
LDL Cholesterol (mg/dl) 92.7 ± 20.8 89.9 ± 27.5 135.9 ± 35.7 160.5 ± 22.6 110.5 ± 34.1 123.1 ± 16.4 0.119 
Triglycerides (mg/dl) 79.7 ± 23.4 43 ± 15.6 75.3 ± 7.5 96.3 ± 52.3 84.7 ± 35.2 94.0 ± 34.7 0.095 
CRP (mg/dl)  0.21 ± 0.16 1.36 ± 1.84 0.35 ± 0.07 0.47 ± 0.37 0.60 ± 0.45 0.85 ± 0.78 0.91 
 
       
Mean EVs diameter (nm) 125 ± 8.9 126 ± 11.3 119.5 ± 7.4 120.4 ± 11.4 114.5 ± 8.8 116.6 ± 7.9 0.139 
EVs/ml plasma (x 10
6
) 3,545 ± 409 3,831 ± 980 3,238 ± 707 5,279 ± 556 4,263 ± 1,432 4,944 ± 2623 0.04 
 
BMI: Body mass index, WtH: Waist to hip ratio, SBP: Systolic blood pressure, DBP: 
Diastolic blood pressure, HOMA-IR: Homeostatic model assessment of insulin 
resistance, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, EVs: 
Extracellular vesicles. Significant differences (p<0.05) between lean and obese groups 
are shown in bold. 
Supplemental Table 2 List of commercially available TaqMan® Gene Expression and 
MicroRNA assays used in this study. 
 
Genes Assay ID# MicroRNAs Assay ID# 
Inflammation hsa-let-7b-5p 2619 
IL6 Hs00985639_m1 hsa-miR-106a-5p 2169 
IL8 Hs00174103_m1 hsa-miR-106b-5p 442 
Insulin pathway hsa-miR-122-5p 2245 
GLUT4 Hs00168966_m1 hsa-miR-143-3p 2249 
IRS1 Hs00178563_m1 hsa-miR-145-5p 2278 
PI3KR Hs00933163_m1 hsa-miR-146a-5p 468 
Adipogenesis hsa-miR-146b-5p 1097 
SREBF1 Hs01088679_g1 hsa-miR-150-5p 473 
CEBPA Hs00269972_s1 hsa-miR-155-5p 2623 
ADIPOQ Hs00605917_m1 hsa-miR-186-3p 2105 
ADIPOR1 Hs00360422_m1 hsa-miR-186-5p 2285 
Lipogenesis hsa-miR-194-5p 493 
ACLY Hs00982738_m1 hsa-miR-212-3p 515 
ACACA Hs01046047_m1 hsa-miR-222-3p 2276 
FASN Hs01005622_m1 hsa-miR-223-3p 2295 
ELOVL6 Hs00907564_m1 hsa-miR-26b-5p 407 
Lipolysis hsa-miR-27a-3p 408 
AQP9 Hs01033361_m1 hsa-miR-29c-3p 587 
Type II diabetes hsa-miR-30a-5p 417 
ADIPOR2 Hs00226105_m1 hsa-miR-301a-3p 528 
Fatty Acid alpha oxidation hsa-miR-320a-3p 2277 
PTGS2 Hs00153133_m1 hsa-miR-323a-3p 2227 
HMGB1 pathway hsa-miR-331-3p 545 
CXCL8 Hs00174103_m hsa-miR-338-5p 2658 
IGF1-signaling hsa-miR-342-3p 2260 
STAT3 Hs00374280_m1 hsa-miR-374a-5p 563 
Insulin receptor; Leptin Signaling in obesity hsa-miR-892b 2214 
PDE3B Hs00265322_m1 Housekeeping 
Housekeeping hsa-miR-30c-5p 419 
PPIA Hs99999904_m1 hsa-miR-24-3p 402 
  hsa-miR-484 1821 
 
IL6 and 8: Interleukin 6 and 8, GLUT4: Solute carrier family 2 (facilitated glucose 
transporter), member 4, IRS1: Insulin receptor substrate 1, PI3KR: Phosphoinositide-
3-kinase regulatory subunit 1, SREBF1: Sterol regulatory element binding transcription 
factor 1, CEBPA: CCAAT/enhancer binding protein alpha, ADIPOQ: Adiponectin, 
ADIPOR1: Adiponectin receptor 1, ACLY: ATP citrate lyase, ACACA: Acetyl-CoA 
carboxylase alpha, FASN: Fatty acid synthase, ELOVL6: ELOVL fatty acid elongase 
6, AQP9: Aquaporin 9, ADIPOR2: Adiponectin receptor 2, PTGS2: Prostaglandin-
endoperoxide synthase 2, CXCL8: C-X-C motif chemokine ligand 8, STAT3: Signal 
transducer and activator of transcription 3, PDE3B: Phosphodiesterase 3B, PPIA: 
Peptidylprolyl isomerase A.  
Supplemental Table 3 Nominal variations found in plasma and plasma-derived EVs-
contained miRNAs of obese (BMI≥35 kg/m2) vs. lean (BMI<25 kg/m2) women.  
 
 
Plasma EVs Plasma 
miRNA – Assay ID#  Fold change  p-value  Fold change  p-value  
hsa-miR-331 – 000545 -14.47 0.0114 1.05 0.875 
hsa-miR-320 – 002277 4.74 0.0119 1.65 0.265 
hsa-miR-186 – 002285  -7.73 0.0167  1.57 0.424 
hsa-miR-30a-5p – 000417 4.20 0.0207 -1.22 0.790 
hsa-miR-16 – 000391 -4.68 0.0225 1.56 0.054 
hsa-miR-141* – 002145  5.07 0.0255  1.33 0.34 
hsa-miR-875-5p – 002203  5.11 0.0279 6.02 0.564 
hsa-miR-376a – 000565 138.90 0.0314 2.51 0.147 
hsa-miR-27a – 000408  -5.16 0.0331 -1.78 0.257 
hsa-miR-618 – 001593 3.71 0.0332 -7.37 0.486 
hsa-miR-15b – 000390 -3.07 0.0339 -1.53 0.224 
hsa-miR-342-3p – 002260 -14.39 0.0344 2.99 0.317 
U6-snRNA – 001973e -5.38 0.0421 1.62 0.460 
hsa-miR-25 – 000403 2101.61 0.0467 -1.84 0.324 
hsa-miR-1290– 002863  7.74 0.0475  2.83 0.214 
hsa-miR-432 – 001026  378.48 0.0635  1.62 0.377 
hsa-miR-378 – 002243 2.22 0.0804 -2.06 0.319 
hsa-miR-103 – 000439 -2.33 0.084 -1.78 0.257 
hsa-miR-520D-3P – 002743 6.43 0.097 2.36 0.346 
hsa-miR-892b – 002214  2.66 0.099  4.73 0.027 
  
Supplemental Table 4 Association between clinical outputs (n=12 individuals, 6 lean 
and 6 obese women) and gene expression measures assessed in mature adipocytes after 
treatment with plasma EVs (~250,000 plasma EVs/µl, 24 h, 3 biological 
replicates/treatment). 
 
 
Age (y) BMI (kg/m2) Glucose (mg/dl) Insulin (µIU/l) HOMA-IR HbA1c (%) 
Inflammation 
IL6 r=-0.08 (0.638) r=-0.197 (0.224) r=-0.357 (0.024) r=-0.462 (0.003) r=-0.459 (0.003) r=-0.644 (<0.0001) 
IL8 r=-0.424 (0.009) r=-0.220 (0.173) r=-0.569 (<0.0001) r=-0.175 (0.28) r=-0.25 (0.12) r=-0.317 (0.059) 
Insulin pathway 
GLUT4 r=-0.042 (0.796) r=-0.471 (0.001) r=0.03 (0.85) r=0.358 (0.023) r=0.497 (0.001) r=0.036 (0.826) 
IRS1 r=0.288 (0.079) r=0.483 (0.001) r=-0.089 (0.582) r=0.356 (0.022) r=0.246 (0.121) r=0.359 (0.027) 
PI3KR r=0.076 (0.643) r=0.172 (0.265) r=-0.221 (0.149) r=-0.061 (0.695) r=-0.073 (0.64) r=-0.166 (0.307) 
Adipogenesis 
SREBF1 r=0.230 (0.183) r=-0.206 (0.214) r=0.105 (0.531) r=-0.511 (0.001) r=-0.408 (0.011) r=-0.408 (0.015) 
CEBPA r=-0.089 (0.621) r=-0.619 (<0.0001) r=0.13 (0.45) r=-0.092 (0.593) r=0.061 (0.725) r=-0.141 (0.435) 
ADIPOQ r=0.373 (0.030) r=-0.041 (0.808) r=-0.083 (0.619) r=-0.212 (0.201) r=-0.18 (0.281) r=-0.092 (0.598) 
ADIPOR1 r=0.112 (0.514) r=-0.291 (0.072) r=0.188 (0.253) r=-0.166 (0.314) r=-0.073 (0.661) r=-0.281 (0.097) 
Lipogenesis 
ACLY r=-0.034 (0.842) r=-0.391 (0.013) r=0.059 (0.716) r=-0.320 (0.044) r=-0.228 (0.157) r=-0.346 (0.039) 
ACACA r=-0.143 (0.361) r=-0.373 (0.01) r=0.012 (0.936) r=-0.041 (0.785) r=0.005 (0.973) r=-0.11 (0.481) 
FASN r=-0.332 (0.059) r=-0.550 (0.001) r=-0.150 (0.381) r=0.424 (0.014) r=0.550 (0.001) r=-0.136 (0.452) 
ELOVL6 r=-0.009 (0.952) r=-0.277 (0.057) r=-0.093 (0.531) r=-0.394 (0.006) r=-0.341 (0.018) r=-0.322 (0.033) 
Lipolysis 
AQP9 r=-0.188 (0.294) r=-0.272 (0.109) r=-0.104 (0.548) r=-0.227 (0.184) r=-0.189 (0.27) r=-0.496 (0.003) 
Type II diabetes 
ADIPOR2 r=0.226 (0.107) r=0.031 (0.823) r=0.293 (0.028) r=0.29 (0.03) r=0.269 (0.045) r=0.411 (0.002) 
Fatty Acid alpha oxidation 
PTGS2 r=0.092 (0.519) r=-0.178 (0.193) r=-0.029 (0.843) r=-0.02 (0.887) r=-0.007 (0.995) r=-0.317 (0.024) 
HMGB1 pathway 
CXCL8 r=-0.34 (0.014) r=0.22 (0.106) r=-0.15 (0.273) r=0.128 (0.35) r=0.088 (0.524) r=0.149 (0.296) 
IGF1-signaling 
STAT3 r=0.283 (0.044) r=0.126 (0.362) r=0.39 (0.004) r=0.313 (0.021) r=0.295 (0.03) r=0.416 (0.003) 
Insulin receptor; Leptin Signaling in obesity 
PDE3B r=0.176 (0.212) r=0.044 (0.746) r=0.3 (0.024) r=0.284 (0.033) r=0.238 (0.078) r=0.37 (0.007) 
 
BMI: Body mass index, HbA1c: Glycated haemoglobin, HOMA-IR: Homeostatic 
model assessment of insulin resistance, IL6 and 8: Interleukin 6 and 8, GLUT4: Solute 
carrier family 2 (facilitated glucose transporter), member 4, IRS1: Insulin receptor 
substrate 1, PI3KR: Phosphoinositide-3-kinase regulatory subunit 1, SREBF1: Sterol 
regulatory element binding transcription factor 1, CEBPA: CCAAT/enhancer binding 
protein alpha, ADIPOQ: Adiponectin, ADIPOR1: Adiponectin receptor 1, ACLY: 
ATP citrate lyase, ACACA: Acetyl-CoA carboxylase alpha, FASN: Fatty acid 
synthase, ELOVL6: ELOVL fatty acid elongase 6, AQP9: Aquaporin 9, ADIPOR2: 
Adiponectin receptor 2, PTGS2: Prostaglandin-endoperoxide synthase 2, CXCL8: C-
X-C motif chemokine ligand 8, STAT3: Signal transducer and activator of transcription 
3, PDE3B: Phosphodiesterase 3B. Significant differences (p<0.05) are shown in bold. 
  
Supplemental Table 5 Genes involved in metabolism with seeding sequences reported 
and empirically validated for miRNAs found in plasma EVs. 
 
Gene Canonical Pathway 
# of miRNAs 
in obese EVs 
# of miRNAs 
in lean EVs 
miRNAs 
PTGS2 Fatty Acid alpha oxidation 3 1 miR-155-5p, let-7b-5p, miR-146a/b-5p 
ADIPOR2 Type II diabetes 2 0 let-7b-5p, miR-892b 
CXCL8 HMGB1 4 1 miR-155-5p, let-7b-5p, miR-106a-5p, miR-146a/b-5p  
STAT3 IGF1-signaling 3 1 miR-155-5p, let-7b-5p, miR-106a-5p, miR-301a-3p 
PDE3B Insulin receptor; Leptin Signaling in obesity 1 2 miR-106a-5p, miR-301a-3p, miR-145-5p 
 
 
Supplemental Figure 1 Absolute cycle thresholds (Cts) and normalized microRNA (miRNA) density in plasma and plasma 
extracellular vesicles (EVs).  
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Cts and normalized miRNA density in plasma 
Cts and normalized miRNA density in plasma EVs 
A B 
Supplemental Figure 2 A. Detection patterns and B. cluster analysis of miRNA profiles assessed in pooled plasma EVs and 
pooled paired-plasma samples. “Undetermined” stands for Ct values ≥ 37.  
Supplemental Figure 3 Venn diagram of miRNAs with Ct values < 35 in all samples/group and multiple sequence alignment 
analysis comparing the miRNAs found in lean/obese plasma and obese EVs (2), lean/obese plasma and lean EVs (9), and 
lean/obese and lean/obese EVs (47 miRNAs).  
MIR-15 family MIR-17 family 
MIR-30 family 
       hsa-miR-15b-5p 
       hsa-miR-16-5p 
       hsa-miR-17-5p 
       hsa-miR-20a-5p 
       hsa-miR-20b-5p 
       hsa-miR-106a/b-5p 
       hsa-miR-30a-5p 
       hsa-miR-30b 
       hsa-miR-30c-5p 
Supplemental Figure 4 Estimated tissue origin of miRNAs found in plasma EVs grouped according to the shared family.  
Normalized results: Heatmap in EVs Normalized results: Heatmap in plasma 
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Supplemental Figure 5 Normalized miRNA clustering and heatmaps in plasma and plasma EVs.  
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